Samrat Pharmachem Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Samrat Pharmachem has a total shareholder equity of ₹650.0M and total debt of ₹84.5M, which brings its debt-to-equity ratio to 13%. Its total assets and total liabilities are ₹1.2B and ₹567.4M respectively. Samrat Pharmachem's EBIT is ₹36.4M making its interest coverage ratio 5.5. It has cash and short-term investments of ₹97.4M.
Anahtar bilgiler
13.0%
Borç/özkaynak oranı
₹84.55m
Borç
| Faiz karşılama oranı | 5.5x |
| Nakit | ₹97.36m |
| Eşitlik | ₹649.97m |
| Toplam yükümlülükler | ₹567.39m |
| Toplam varlıklar | ₹1.22b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 530125's short term assets (₹1.0B) exceed its short term liabilities (₹564.0M).
Uzun Vadeli Yükümlülükler: 530125's short term assets (₹1.0B) exceed its long term liabilities (₹3.4M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 530125 has more cash than its total debt.
Borcun Azaltılması: 530125's debt to equity ratio has reduced from 30.3% to 13% over the past 5 years.
Borç Kapsamı: 530125's debt is well covered by operating cash flow (111.3%).
Faiz Kapsamı: 530125's interest payments on its debt are well covered by EBIT (5.5x coverage).